Effect of magnesium sulfate combined with labetalol on serum sFlt‑1/PlGF ratio in patients with early‑onset severe pre‑eclampsia
- Ying Wang
- Jing Bao
- Min Peng
Affiliations: Department of Obstetrics, Maternity and Child Health Care Hospital of Hubei, Wuhan, Hubei 430000, P.R. China
- Published online on: October 27, 2020 https://doi.org/10.3892/etm.2020.9406
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The aim of the present study was to investigate the therapeutic effect of magnesium sulfate combined with labetalol on the early‑onset severe pre‑eclampsia (ES‑PE) and explore the role of soluble fms‑like tyrosine kinase‑1 (sFlT‑1), placental growth factor (PlGF), and sFlt‑1/PlGF ratio in the treatment. A total of 164 ES‑PE patients admitted to the Maternity and Child Health Care Hospital of Hubei (Wuhan, China) were assigned to this observational study. Among them, 83 patients were enrolled in group A and treated with magnesium sulfate combined with labetalol hydrochloride, and 81 patients were enrolled in group B and treated with magnesium sulfate. The therapeutic effect, adverse reactions and pregnancy outcomes in the two groups were analyzed. Serum sFlt‑1 and PlGF concentrations, before and after treatment, were measured by enzyme‑linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value of pre‑treatment serum sFlt‑1/PlGF ratio for the clinical outcome. The effective rate was significantly higher in group A than that in group B. Group A presented superior pregnancy outcomes over group B. The serum sFlt‑1 concentration and sFlt‑1/PlGF ratio after treatment were significantly lower than those before treatment in groups A and B, whereas PlGF concentration was significantly higher after treatment in both groups. After treatment, group A had markedly lower serum sFlt‑1 concentration and sFlt‑1/PlGF ratio than group B, and markedly higher PlGF concentration than group B. The area under curve (AUC) of serum sFlt‑1/PlGF ratio before treatment for the prediction of the clinical efficacy was 0.737. In conclusion, magnesium sulfate combined with labetalol could be effectively used for the treatment of ES‑PE. The results of ELISA revealed that the balance of sFlT‑1 and PlGF was improved after treatment and the sFlT‑1/PlGF ratio was decreased. The assessment of sFlt‑1/PlGF ratio before treatment was shown to have a certain predictive value for the efficacy of ES‑PE treatment.